Pharmaceuticals

About a Universal Right of Access to Health, Intellectual Property, and Other Legal Intricacies

In its recent extraordinary Assembly in November 2021, the WHO agreed to "launch a process to develop a historic global agreement on prevention, preparedness and response to pandemics", which leads us to raise the importance of having a global treaty on this issue, not only of course, in our condition as human beings, but from the point of view of our condition as lawyers dedicated to intellectual property.

Cannabis: A Promising Future

Read more about Cannabis: A Promising Future
106 views

The legalization of cannabis for medicinal and scientific purposes constitutes a relevant topic for both Colombian industry and the Colombian economy.

Protection of Trademarks and Patents in light of Covid-19

In the course of the Covid-19 pandemic, companies have shown a certain reluctance to register and maintain industrial property rights, says Christoph Jonas. He gives recommendations how to actively manage IP rights at present.

USPTO Grants Further Limited Relief in Light of COVID-19

The U.S. Patent and Trademark Office granted additional, limited relief to those most impacted by COVID-19 for certain patent and trademark-related fees and deadlines. This relief is far more limited than the previous relief and aims primarily to assist individuals and small businesses.

"Orphan" Drugs

Read more about "Orphan" Drugs
65 views

A drug is called “orphan” when it is intended for treating rare diseases. This situation deters the pharmaceutical industries from investing in this kind of products.

DNA Testing in Contentious Probate Claims

In the present case, the Court noted that the provision of a sample of saliva was painless, quick and carried no appreciable risk to the health of the donor of the sample. The evidence of the DNA testing was likely to be very useful indeed to the Court.